Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 5, 2015-05 ,pp. : 789-800

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to in vitro and physiologically‐based pharmacokinetic assessment of the drug–drug interaction potential of canagliflozin

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 2, 2018-02 ,pp. : 392-393

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1012-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of Drug–Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically‐Based Pharmacokinetic Modelling

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 122, Iss. 3, 2018-03 ,pp. : 331-340

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1378-1385

John Wiley & Sons Inc

Access to resources Recommend Favorite